{"id":522,"date":"2026-01-21T10:28:55","date_gmt":"2026-01-21T14:28:55","guid":{"rendered":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=522"},"modified":"2026-01-21T10:28:56","modified_gmt":"2026-01-21T14:28:56","slug":"us-supreme-court-grants-certiorari-in-hikma-v-amarin-placing-skinny-label-inducement-in-focus","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2026\/01\/21\/us-supreme-court-grants-certiorari-in-hikma-v-amarin-placing-skinny-label-inducement-in-focus\/","title":{"rendered":"U.S. Supreme Court Grants Certiorari in Hikma\u00a0v. Amarin, Placing &#8220;Skinny Label&#8221; Inducement in Focus"},"content":{"rendered":"\n<p>On January 16, 2026, the Supreme Court of the United States granted certiorari in\u00a0<em>Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.<\/em>\u00a0(No. 24-889) to address when induced-infringement liability can attach to a generic drug launched under a \u201cskinny label.\u201d The grant centers on review of the Federal Circuit\u2019s decision allowing Amarin\u2019s inducement claims to proceed notwithstanding Hikma\u2019s carveout, and it tees up the relationship between the Food and Drug Administration\u2019s (FDA) carveout pathway and 35 U.S.C. \u00a7 271(b).<\/p>\n\n\n\n<p>Read the full <em><a href=\"https:\/\/www.duanemorris.com\/alerts\/us_supreme_court_grants_certiorari_hikma_amarin_placing_skinny_label_inducement_focus_0126.html\">Alert <\/a><\/em>on the Duane Morris LLP website. <\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On January 16, 2026, the Supreme Court of the United States granted certiorari in\u00a0Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.\u00a0(No. 24-889) to address when induced-infringement liability can attach to a generic drug launched under a \u201cskinny label.\u201d The grant centers on review of the Federal Circuit\u2019s decision allowing Amarin\u2019s inducement claims to proceed notwithstanding &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2026\/01\/21\/us-supreme-court-grants-certiorari-in-hikma-v-amarin-placing-skinny-label-inducement-in-focus\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;U.S. Supreme Court Grants Certiorari in Hikma\u00a0v. Amarin, Placing &#8220;Skinny Label&#8221; Inducement in Focus&#8221;<\/span><\/a><\/p>\n","protected":false},"author":109,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"ppma_author":[533,527],"class_list":["post-522","post","type-post","status-publish","format-standard","hentry","category-general"],"authors":[{"term_id":533,"user_id":109,"is_guest":0,"slug":"jluo","display_name":"Jason Luo, Ph.D.","avatar_url":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-content\/uploads\/sites\/15\/2014\/08\/luojiazhong-125x150.jpg","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""},{"term_id":527,"user_id":33,"is_guest":0,"slug":"frball","display_name":"Frederick R. Ball","avatar_url":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-content\/uploads\/sites\/15\/2018\/10\/ballfrederick-125x150.jpg","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/109"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=522"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/522\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=522"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}